Compare, Analyse AJANTA PHARMA with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AJANTA PHARMA   ACTAVIS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
ACTAVIS
Dec-18
AJANTA PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,42213,781-   
Low Rs8989,244-   
Sales per share (Unadj.) Rs233.53,380.5-  
Earnings per share (Unadj.) Rs44.0-1,088.9-  
Cash flow per share (Unadj.) Rs52.2356.2-  
Dividends per share (Unadj.) Rs9.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs255.113,942.9-  
Shares outstanding (eoy) m88.02332.60-   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.03.4 145.8%   
Avg P/E ratio x26.4-10.6 -249.5%  
P/CF ratio (eoy) x22.232.3 68.8%  
Price / Book Value ratio x4.50.8 550.6%  
Dividend payout %20.50-   
Avg Mkt Cap Rs m102,0813,829,128 2.7%   
No. of employees `0006.816.9 40.2%   
Total wages/salary Rs m4,3070-   
Avg. sales/employee Rs Th3,022.666,529.6 4.5%   
Avg. wages/employee Rs Th633.40-   
Avg. net profit/employee Rs Th569.1-21,429.2 -2.7%   
INCOME DATA
Net Sales Rs m20,5541,124,350 1.8%  
Other income Rs m21121,501 1.0%   
Total revenues Rs m20,7651,145,851 1.8%   
Gross profit Rs m5,66429,464 19.2%  
Depreciation Rs m721480,635 0.1%   
Interest Rs m1264,881 0.0%   
Profit before tax Rs m5,143-494,552 -1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0126,131 0.0%   
Tax Rs m1,273-6,267 -20.3%   
Profit after tax Rs m3,870-362,154 -1.1%  
Gross profit margin %27.62.6 1,051.6%  
Effective tax rate %24.81.3 1,953.3%   
Net profit margin %18.8-32.2 -58.5%  
BALANCE SHEET DATA
Current assets Rs m11,812461,150 2.6%   
Current liabilities Rs m3,776407,948 0.9%   
Net working cap to sales %39.14.7 826.3%  
Current ratio x3.11.1 276.7%  
Inventory Days Days7720 395.1%  
Debtors Days Days8266 123.1%  
Net fixed assets Rs m14,398127,270 11.3%   
Share capital Rs m1750-   
"Free" reserves Rs m22,2770-   
Net worth Rs m22,4524,637,419 0.5%   
Long term debt Rs m71,633,003 0.0%   
Total assets Rs m26,9627,249,341 0.4%  
Interest coverage x444.3-6.6 -6,709.6%   
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x0.80.2 491.5%   
Return on assets %14.4-4.1 -351.1%  
Return on equity %17.2-7.8 -220.7%  
Return on capital %23.0-4.8 -474.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m8,5800-   
CASH FLOW
From Operations Rs m3,748401,688 0.9%  
From Investments Rs m-2,228220,675 -1.0%  
From Financial Activity Rs m-1,475-689,417 0.2%  
Net Cashflow Rs m45-66,719 -0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.22 Rs / USD

Compare AJANTA PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare AJANTA PHARMA With: JUBILANT LIFE SCIENCES  PROCTER & GAMBLE HEALTH  BIOCON   SANOFI INDIA  ORCHID PHARMA LTD  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views On News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS